Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

Canada has joined a global effort designed to help deliver equitable access to COVID-19 vaccines in a move that stands in contrast with a decision taken by the United States not to join.

Prime Minister Justin Trudeau announced Friday that the federal government will spend approximately $220-million on the COVAX Facility to procure up to 15 million vaccine doses for Canadians.

An additional $220-million is being earmarked to purchase doses for low- and middle-income countries, the government said, adding that Canada cannot beat the pandemic unless it is addressed everywhere.

Story continues below advertisement

The hunt for a vaccine to prevent the spread of COVID-19 in Canada is a major preoccupation for the federal government, particularly because officials are concerned about the resurgence of the virus in Quebec, Ontario, British Columbia and Alberta.

Earlier this week, Prime Minister Justin Trudeau warned Canada is at a crossroads and a second wave of the pandemic is already under way in the four biggest provinces. He said figures support this fact; there were 47 new cases when the country went into lockdown in March but more than 1,000 on Tuesday alone.

“We’re on the brink of a fall that could be much worse than the spring,” he said in an address to the country following the Throne Speech on Wednesday.

Canadians must have access to a safe and effective vaccine against COVID-19 no matter where it is developed, the Prime Minister added on Friday.

Earlier this month, the United States said it would not join the COVAX Facility. The World Health Organization (WHO) said more than 170 economies are engaged in discussions to potentially participate in the global initiative.

COVAX is co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the WHO. Its goal is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for all countries.

“Unfortunately, there are a few large countries that have decided not to participate,” Mr. Trudeau said.

Story continues below advertisement

“But I can assure you the number of countries that have stepped up and participated like Canada is ensuring that we are going a long way towards having vaccines accessible for the most vulnerable around the world, which is essential.”

Mr. Trudeau also announced Friday a new vaccine agreement has been reached, bringing the total number of agreements for Canada to six.

Procurement Minister Anita Anand said by supporting the COVAX Facility that Canada is continuing to diversify its investment in a potential supply and it is committing to assist low-income countries.

Mr. Trudeau said an agreement has been reached with AstraZeneca to procure up to 20 million doses of its COVID-19 vaccine candidate.

The government said Friday the new agreement adds to those already reached with Sanofi and GlaxoSmithKline, Johnson & Johnson, Novavax, Pfizer and Moderna.

Mr. Trudeau said the best way to end the COVID-19 pandemic and to keep Canadians healthy is through a safe and effective vaccine.

Story continues below advertisement

At present, there are no vaccines that have been approved to prevent COVID-19 in Canada. Health Canada will review evidence of safety, efficacy and manufacturing quality for each vaccine to determine whether they will be approved for use and made available to Canadians.

Know what is happening in the halls of power with the day’s top political headlines and commentary as selected by Globe editors (subscribers only). Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies